Ad hoc: Evotec SE appoints Dr Christian Wojczewski as CEO
Evotec SE announces the appointment of Dr Christian Wojczewski as Chief Executive Officer of the Company, effective 01 July 2024. Dr Wojczewski holds a degree in chemistry and has over 20 years of...
View ArticleEvotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
The Supervisory Board of Evotec SE has appointed Dr Christian Wojczewski as the Company’s new Chief Executive Officer (“CEO”), effective 01 July 2024. The election was unanimous and is the result of an...
View ArticleEvotec presents fiscal year 2023 results and announces priority reset ...
Evotec SE today reported financial results and corporate updates for the fiscal year ended 31 December 2023 and announced a priority reset to optimise its business to meet evolving market demand and...
View ArticleJust – Evotec Biologics launches J.CHO™ high expression system for ...
Just – Evotec Biologics, the biologics segment of Evotec SE today announced the launch of its proprietary J.CHO™ High Expression System (“J.CHO”) for antibody expression. As part of Just – Evotec...
View ArticleBayer and Evotec collaborate to advance precision cardiology
Bayer and the German-based life science company, Evotec, announced today that they have updated the focus of their strategic collaboration to developing innovative precision treatments for...
View ArticleEvotec partner Kazia reports the successful completion of the ...
Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that the Safety Review Team (SRT) of the EVT801 Phase 1 clinical trial has concluded...
View ArticleEvotec SE to announce results for first quarter 2024 on 22 may 2024
Evotec SE will announce its financial results for the first quarter of 2024 on Wednesday, 22 May 2024.
View ArticleEvotec reports Q1 2024 results and provides corporate update
Evotec SE today announced financial results and corporate updates for the first quarter 2024.
View ArticleEvotec SE today announced receipt of a written notice from NASDAQ
Evotec SE today announced receipt of a written notice (the “Notice”) from NASDAQ on 17 May 2024, stating that the Company is not in compliance with the Listing Rules (the “Rules”) for continued listing.
View ArticleEvotec and CHDI Foundation extend collaboration in Huntington’s disease
Evotec SE has announced the extension of its 20-year collaboration with CHDI Foundation, Inc. (“CHDI”). The collaboration will further our fundamental scientific understanding of the disease and...
View ArticleEvotec, Inserm, Lille University Hospital, Inserm Transfert collaborate
Evotec SE today announced that the Company entered a partnership with Inserm, the French National Institute of Health and Medical Research, Lille University Hospital and Inserm Transfert (the private...
View ArticleEvotec and QIAGEN enter collaboration for enhanced multi-omics data insight
Evotec SE and QIAGEN today announced a collaboration to leverage QIAGEN’s OmicSoft Land Databases through Evotec’s PanOmics data access and analysis platform PanHunter. Combining comprehensive data...
View ArticleAurobac Therapeutics presents its R&D strategy & pipeline
Aurobac Therapeutics, a biopharmaceutical company founded by Boehringer Ingelheim, bioMérieux and Evotec, presented its strategy for the first time today. It aims to address high unmet medical needs...
View ArticleJust – Evotec Biologics completes cGMP clinical manufacturing for FG-3165
Just – Evotec Biologics, Inc., the biologics segment of Evotec SE, announced today that cGMP clinical materials manufactured for FibroGen were cleared for clinical use by the United States Food and...
View ArticleEvotec SE: Results of the Annual General Meeting 2024
Evotec SE today announced that its shareholders approved most of the proposals the Company’s Management put to vote at the Company’s Annual General Meeting 2024 with great majority.
View ArticleEvotec announces progress in neuroscience collaboration with Bristol ...
Evotec SE announced today that the Company has reached important scientific progress within its neuroscience collaboration with Bristol Myers Squibb triggering a research payment of US$ 20 m to Evotec....
View ArticleTubulis Doses First Patient in Phase I/IIa Trial Investigating ADC ...
Tubulis announced today that the first patient has been treated in its first Phase I/IIa trial (NAPISTAR 1-01, NCT06303505). The study is evaluating Tubulis’ next-generation antibody-drug conjugate...
View ArticlebeLAB1407 to develop novel approach for cardiovascular diseases
Evotec SE today announced that the University of Bristol has been granted an award within the framework of the beLAB1407 BRIDGE partnership to develop a novel antisense oligonucleotide (“ASO”) based...
View ArticleJust – Evotec Biologics selected by U.S. DOD for Manufacturing Optimization
Evotec SE today announced that its Seattle-based subsidiary, Just – Evotec Biologics, Inc., was selected by the U.S. Department of Defense (“DOD”) to develop an accelerated monoclonal antibody (“mAb”)...
View ArticleTubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate...
Tubulis announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its lead antibody-drug conjugate (ADC) TUB-040 for the treatment of patients with...
View Article